IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nabriva Therapeutics plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NBRV&src=ctag” target=”_blank”gt;$NBRVlt;/agt; lt;a href=”https://twitter.com/hashtag/ClassAction?src=hash” target=”_blank”gt;#ClassActionlt;/agt;–The
Schall Law Firm, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Nabriva
Therapeutics plc (“Nabriva” or “the Company”) (NASDAQ: NBRV)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.
Investors who purchased the Company’s shares between November 1, 2018
and April 30, 2019, inclusive (the ”Class Period”), are encouraged to
contact the firm before July 8, 2019.
If you are a shareholder who suffered a loss, click
here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm’s website at www.schallfirm.com,
or by email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading
statements to the market. Nabriva’s manufacturers were incapable of
maintaining good manufacturing practices. Because these manufacturers
would be subject to inspection as part of the Company’s New Drug
Application for CONTEPO with the FDA. The poor manufacturing practices
were likely to hurt the chances of the New Drug Application to be
approved. Based on these facts, the Company’s public statements were
false and materially misleading throughout the class period. When the
market learned the truth about Nabriva, investors suffered damages.
Join
the case to recover your losses.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.
Contacts
The Schall Law Firm
Brian Schall, Esq.,
Sherin Mahdavian, Esq.,
www.schallfirm.com
Office:
310-301-3335
Cell: 424-303-1964
info@schallfirm.com